Dorothea M Peters

List of Publications by Year
in descending order

50 papers	2,615 citations	236925 25 h-index	197818 49 g-index
50 all docs	50 docs citations	50 times ranked	3286 citing authors

#	Article	IF	Citations
1	Risk Factors for Phenoconversion in <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder. Annals of Neurology, 2022, 91, 404-416.	5.3	27
2	Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinsonâ€™s disease. Scientific Reports, 2022, 12, 3180.	3.3	10
3	Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinsonâ€™s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. Frontiers in Aging Neuroscience, 2022, 14, 851788.	3.4	7
4	The roles of connectivity and neuronal phenotype in determining the pattern of Î±-synuclein pathology in Parkinson's disease. Neurobiology of Disease, 2022, 168, 105687.	4.4	14
5	Eye tracking identifies biomarkers in Î±-synucleinopathies versus progressive supranuclear palsy. Journal of Neurology, 2022, 269, 4920-4938.	3.6	6
6	Fourâ€Year <scp>Followâ€up</scp> of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomographyâ€“Based Parkinson's Diseaseâ€“Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression. Movement Disorders, 2021, 36, 230-235.	3.9	31
7	Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease. Molecular Medicine, 2021, 27, 111.	4.4	20
8	Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern. Movement Disorders, 2021, , .	3.9	6
9	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2019, 18, 724-735.	10.2	79
10	Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse. Scientific Reports, 2019, 9, 13359.	3.3	12
11	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	7.6	636
12	Widespread microglial activation in multiple system atrophy. Movement Disorders, 2019, 34, 564-568.	3.9	41
13	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 229-239.	2.8	12
14	Mitochondrial damage by Î±-synuclein causes cell death in human dopaminergic neurons. Cell Death and Disease, 2019, 10, 865.	6.3	112
15	Validation of a new data-driven automated algorithm for muscular activity detection in REM sleep behavior disorder. Journal of Neuroscience Methods, 2019, 312, 53-64.	2.5	23
16	The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease. Journal of Nuclear Medicine, 2018, 59, 1437-1444.	5.0	80
17	The spectrum of â€œoffâ€•in Parkinson's disease: What have we learned over 40 years?. Parkinsonism and Related Disorders, 2018, 51, 9-16.	2.2	115
18	Calcium-activated SK potassium channels are key modulators of the pacemaker frequency in locus coeruleus neurons. Molecular and Cellular Neurosciences, 2018, 88, 330-341.	2.2	35

#	Article	IF	Citations
19	Is increased spinal nociception another hallmark for Parkinsonâ€™s disease?. Journal of Neurology, 2017, 264, 570-575.	3.6	9
20	Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons. Neuroscience, 2017, 365, 137-145.	2.3	12
21	Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Scientific Reports, 2017, 7, 11469.	3.3	52
22	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Movement Disorders, 2017, 32, 1482-1486.	3.9	67
23	Mutant Î±-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease. Journal of Neuroscience, 2017, 37, 47-57.	3.6	22
24	Recent advances in treating Parkinsonâ€™s disease. F1000Research, 2017, 6, 260.	1.6	92
25	Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wildâ€type and <scp>MAPT</scp> transgenic mice. Journal of Neurochemistry, 2016, 139, 624-639.	3.9	26
26	Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension. CNS Drugs, 2016, 30, 749-760.	5.9	11
27	Biceps electromyography in dialeptic and automotor seizures with and without secondary generalization. Clinical Neurophysiology, 2016, 127, 1163-1169.	1.5	3
28	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Movement Disorders, 2016, 31, 742-747.	3.9	29
29	<scp>DTI</scp> and <scp>VBM</scp> reveal white matter changes without associated gray matter changes in patients with idiopathic restless legs syndrome. Brain and Behavior, 2015, 5, e00327.	2.2	26
30	Piericidin A Aggravates Tau Pathology in P301S Transgenic Mice. PLoS ONE, 2014, 9, e113557.	2.5	15
31	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open, 2014, 4, e005122-e005122.	1.9	35
32	Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Neuropharmacology, 2014, 79, 212-221.	4.1	21
33	Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation. Journal of Chemical Neuroanatomy, 2014, 61-62, 169-175.	2.1	7
34	Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan). Journal of Nuclear Medicine, 2014, 55, 1281-1287.	5.0	19
35	Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Experimental Neurology, 2014, 253, 113-125.	4.1	39
36	Trifluoperazine rescues human dopaminergic cells from wild-type Î±-synuclein-induced toxicity. Neurobiology of Aging, 2014, 35, 1700-1711.	3.1	48

#	Article	IF	Citations
37	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. Annals of Clinical and Translational Neurology, 2014, 1, 822-832.	3.7	114
38	Do different assays for human acylated ghrelin concentrations provide comparable results?. Neuroendocrinology Letters, 2014, 35, 37-41.	0.2	0
39	Shortâ€term effects of coenzyme Q₁₀ in progressive supranuclear palsy: A randomized, placeboâ€controlled trial. Movement Disorders, 2008, 23, 942-949.	3.9	135
40	Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Medicine, 2008, 9, 228-239.	1.6	105
41	Rasagiline. Drugs and Aging, 2005, 22, 93-94.	2.7	1
42	Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. Movement Disorders, 2003, 18, 430-432.	3.9	49
43	Role of dopamine transporter SPECT for the practitioner and the general neurologist. Movement Disorders, 2003, 18, S9-S15.	3.9	7
44	Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson??s Disease. Pharmacoeconomics, 2001, 19, 1013-1038.	3.3	105
45	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	3.9	47
46	Autonomic Seizures Versus Syncope in 18q- Deletion Syndrome: A Case Report. Epilepsia, 2000, 41, 1039-1043.	5.1	22
47	Treatment of Idiopathic Restless Legs Syndrome (RLS) with the D2-agonist Cabergoline â€" An Open Clinical Trial. Sleep, 2000, 23, 1-6.	1.1	67
48	Costs of drug treatment in Parkinson's disease. Movement Disorders, 1998, 13, 249-254.	3.9	74
49	Letters to the Editor. Movement Disorders, 1998, 13, 749-753.	3.9	21
50	Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome. Movement Disorders, 1998, 13, 820-824.	3.9	69